G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent

Cytokine and Growth Factor Reviews

Volumn 25, Issue 4, 2014, Pages 355-367

  Bendall, Linda J ^a   Bradstock, Kenneth F ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Bone marrow microenvironment; Chemotherapy; G CSF; Stem cell mobilization; Stem cell transplantation

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; ALT 1188; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; FINGOLIMOD; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; ME6TREN; MELPHALAN; PLERIXAFOR; POL 6326; PONESIMOD; PROTEIN INHIBITOR; PROTEINASE; PURINERGIC P2Y RECEPTOR AGONIST; S1P1 RECEPTOR AGONIST; TG 0054; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE; VINCRISTINE; VLA 4 INHIBITOR; CHEMOKINE RECEPTOR CXCR4; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW DEPRESSION; BONE PAIN; CANCER CELL; CELL DISRUPTION; CELL FUNCTION; CELL PROTECTION; DIABETES MELLITUS; DONOR SELECTION; DRUG EFFECT; DRUG SAFETY; HEMATOPOIETIC STEM CELL; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LUNG INFILTRATE; MALAISE; NAUSEA; NERVOUS SYSTEM FUNCTION; NEUTROPENIA; NIGHT SWEAT; NONHUMAN; PHAGOCYTE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RESPIRATORY DISTRESS; REVIEW; SPLEEN RUPTURE; STEM CELL MOBILIZATION; BONE MARROW CELL; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKOCYTE ACTIVATION; METABOLISM; NEUTROPHIL;

BONE MARROW CELLS; CHEMOKINE CXCL12; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; NEUTROPENIA; NEUTROPHIL ACTIVATION; NEUTROPHILS; RECEPTORS, CXCR4;

EID: 84908021698     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.011     Document Type: Review

References (147)

1. Bradley T.R., Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966, 44:287-299.
2. Ichikawa Y., Pluznik D.H., Sachs L. In vitro control of the development of macrophage and granulocyte colonies. Proc Natl Acad Sci U S A 1966, 56:488-495.
3. Nicola N.A., Metcalf D., Matsumoto M., Johnson G.R. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem 1983, 258:9017-9023.
4. Welte K., Platzer E., Lu L., Gabrilove J.L., Levi E., Mertelsmann R., et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A 1985, 82:1526-1530.
5. Nagata S., Tsuchiya M., Asano S., Kaziro Y., Yamazaki T., Yamamoto O., et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986, 319:415-418.
6. Souza L.M., Boone T.C., Gabrilove J., Lai P.H., Zsebo K.M., Murdock D.C., et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986, 232:61-65.
7. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010, 10:425-434.
8. Lieschke G.J., Grail D., Hodgson G., Metcalf D., Stanley E., Cheers C., et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994, 84:1737-1746.
9. Liu F., Wu H.Y., Wesselschmidt R., Kornaga T., Link D.C. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996, 5:491-501.
10. Fukunaga R., Ishizaka-Ikeda E., Nagata S. Purification and characterization of the receptor for murine granulocyte colony-stimulating factor. J Biol Chem 1990, 265:14008-14015.
11. Cebon J., Layton J.E., Maher D., Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 1994, 86:265-274.
12. Kawakami M., Tsutsumi H., Kumakawa T., Abe H., Hirai M., Kurosawa S., et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990, 76:1962-1964.
13. Roberts A., Nicola N. Granulocyte colony-stimulating factor. Colony stimulating factors, molecular and cellular biology 1996, Marcel Dekker, New York. J. Garland, P. Quesenberry, D. Hilton (Eds.).
14. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
15. Sano E., Ohashi K., Sato Y., Kashiwagi M., Joguchi A., Naruse N. A possible role of autogenous IFN-beta for cytokine productions in human fibroblasts. J Cell Biochem 2007, 100:1459-1476.
16. Colotta F., Re F., Polentarutti N., Sozzani S., Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992, 80:2012-2020.
17. Gregory A.D., Hogue L.A., Ferkol T.W., Link D.C. Regulation of systemic and local neutrophil responses by G-CSF during pulmonary Pseudomonas aeruginosa infection. Blood 2007, 109:3235-3243.
18. Smith W.B., Gamble J.R., Vadas M.A. The role of granulocyte-macrophage and granulocyte colony-stimulating factors in neutrophil transendothelial migration: comparison with interleukin-8. Exp Hematol 1994, 22:329-334.
19. Bober L.A., Grace M.J., Pugliese-Sivo C., Rojas-Triana A., Waters T., Sullivan L.M., et al. The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacology 1995, 29:111-119.
20. Tanimura M., Kobuchi H., Utsumi T., Yoshioka T., Kataoka S., Fujita Y., et al. Neutrophil priming by granulocyte colony stimulating factor and its modulation by protein kinase inhibitors. Biochem Pharmacol 1992, 44:1045-1052.
21. Gabrilove J.L., Jakubowski A., Scher H., Sternberg C., Wong G., Grous J., et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988, 318:1414-1422.
22. Bronchud M.H., Scarffe J.H., Thatcher N., Crowther D., Souza L.M., Alton N.K., et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987, 56:809-813.
23. Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29A:319-324.
24. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325:164-170.
25. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
26. Dale D.C., Bolyard A.A., Schwinzer B.G., Pracht G., Bonilla M.A., Boxer L., et al. The severe chronic neutropenia international registry: 10-year follow-up report. Support Cancer Ther 2006, 3:220-231.
27. Tichelli A., Schrezenmeier H., Socie G., Marsh J., Bacigalupo A., Duhrsen U., et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011, 117:4434-4441.
28. Newburger P.E., Dale D.C. Evaluation and management of patients with isolated neutropenia. Semin Hematol 2013, 50:198-206.
29. Rosenberg P.S., Zeidler C., Bolyard A.A., Alter B.P., Bonilla M.A., Boxer L.A., et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010, 150:196-199.
30. Hari P.N., McCarthy P.L. Multiple myeloma: future directions in autologous transplantation and novel agents. Biol Blood Marrow Transplant 2013, 19:S20-S25.
31. Gascoyne R.D., Moskowitz C., Shea T.C. Controversies in BMT for lymphoma. Biol Blood Marrow Transplant 2013, 19:S26-S32.
32. Cavazzana-Calvo M., Andre-Schmutz I., Fischer A. Haematopoietic stem cell transplantation for SCID patients: where do we stand. Br J Haematol 2013, 160:146-152.
33. Parmar S., Ritchie D.S. Allogeneic transplantation as anticancer immunotherapy. Curr Opin Immunol 2014, 27c:38-45.
34. Tamura M., Hattori K., Nomura H., Oheda M., Kubota N., Imazeki I., et al. Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF). Biochem Biophys Res Commun 1987, 142:454-460.
35. Duhrsen U., Villeval J.L., Boyd J., Kannourakis G., Morstyn G., Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988, 72:2074-2081.
36. DeLuca E., Sheridan W.P., Watson D., Szer J., Begley C.G. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 1992, 66:893-899.
37. Sheridan W.P., Begley C.G., Juttner C.A., Szer J., To L.B., Maher D., et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992, 339:640-644.
38. Grigg A.P., Roberts A.W., Raunow H., Houghton S., Layton J.E., Boyd A.W., et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995, 86:4437-4445.
39. Russell N.H., Byrne J.L. Allogeneic transplantation using peripheral blood stem cells. Best Pract Res Clin Haematol 2001, 14:685-700.
40. Favre G., Beksac M., Bacigalupo A., Ruutu T., Nagler A., Gluckman E., et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003, 32:873-880.
41. Liu F., Poursine-Laurent J., Link D.C. Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood 2000, 95:3025-3031.
42. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978, 4:7-25.
43. Levesque J., Takamatsu Y., Nilsson S., Haylock D., Simmons P. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001, 98:1289-1297.
44. Levesque J., Hendy J., Takamatsu Y., Simmons P., Bendall L. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003, 111:187-196.
45. Papayannopoulou T., Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993, 90:9374-9378.
46. Liles W., Broxmeyer H., Rodger E., Wood B., Hubel K., Cooper S., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
47. Pelus L.M., Bian H., King A.G., Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood 2004, 103:110-119.
48. Levesque J.P., Liu F., Simmons P.J., Betsuyaku T., Senior R.M., Pham C., et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004, 104:65-72.
49. -/- mice. Exp Hematol 2003, 31:1126-1134.
50. Lambeir A.M., Proost P., Durinx C., Bal G., Senten K., Augustyns K., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001, 276:29839-29845.
51. Broxmeyer H.E., Hoggatt J., O'Leary H.A., Mantel C., Chitteti B.R., Cooper S., et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 2012, 18:1786-1796.
52. Juarez J.G., Harun N., Thien M., Welschinger R., Baraz R., Dela Pena A., et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood 2012, 119:707-716.
53. Golan K., Vagima Y., Ludin A., Itkin T., Cohen-Gur S., Kalinkovich A., et al. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood 2012, 119:2478-2488.
54. Ratajczak M.Z., Lee H., Wysoczynski M., Wan W., Marlicz W., Laughlin M.J., et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia 2010, 24:976-985.
55. Yanai N., Matsui N., Furusawa T., Okubo T., Obinata M. Sphingosine-1-phosphate and lysophosphatidic acid trigger invasion of primitive hematopoietic cells into stromal cell layers. Blood 2000, 96:139-144.
56. Rosen H., Goetzl E.J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005, 5:560-570.
57. Schwab S., Pereira J., Matloubian M., Xu Y., Huang Y., Cyster J. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005, 309:1735-1739.
58. Pappu R., Schwab S.R., Cornelissen I., Pereira J.P., Regard J.B., Xu Y., et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007, 316:295-298.
59. Fukuhara S., Simmons S., Kawamura S., Inoue A., Orba Y., Tokudome T., et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 2012, 122:1416-1426.
60. Massberg S., Schaerli P., Knezevic-Maramica I., Köllnberger M., Tubo N., Moseman E., et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 2007, 131:994-1008.
61. Semerad C.L., Christopher M.J., Liu F., Short B., Simmons P.J., Winkler I., et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005, 106:3020-3027.
62. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006, 12:657-664.
63. Ferraro F., Lymperi S., Mendez-Ferrer S., Saez B., Spencer J.A., Yeap B.Y., et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011, 3:104ra1.
64. Shivtiel S., Kollet O., Lapid K., Schajnovitz A., Goichberg P., Kalinkovich A., et al. CD45 regulates retention, motility, and numbers of hematopoietic progenitors, and affects osteoclast remodeling of metaphyseal trabecules. J Exp Med 2008, 205:2381-2395.
65. Miyamoto K., Yoshida S., Kawasumi M., Hashimoto K., Kimura T., Sato Y., et al. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med 2011, 208:2175-2181.
66. Winkler I.G., Sims N.A., Pettit A.R., Barbier V., Nowlan B., Helwani F., et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010, 116:4815-4828.
67. Hirbe A.C., Uluckan O., Morgan E.A., Eagleton M.C., Prior J.L., Piwnica-Worms D., et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood 2007, 109:3424-3431.
68. Asada N., Katayama Y., Sato M., Minagawa K., Wakahashi K., Kawano H., et al. Matrix-embedded osteocytes regulate mobilization of hematopoietic stem/progenitor cells. Cell Stem Cell 2013, 12:737-747.
69. Christopher M.J., Rao M., Liu F., Woloszynek J.R., Link D.C. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 2011, 208:251-260.
70. Chow A., Lucas D., Hidalgo A., Mendez-Ferrer S., Hashimoto D., Scheiermann C., et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011, 208:261-271.
71. Katayama Y., Battista M., Kao W.M., Hidalgo A., Peired A.J., Thomas S.A., et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006, 124:407-421.
72. Mendez-Ferrer S., Battista M., Frenette P.S. Cooperation of beta(2)- and beta(3)-adrenergic receptors in hematopoietic progenitor cell mobilization. Ann N Y Acad Sci 2010, 1192:139-144.
73. Lucas D., Bruns I., Battista M., Mendez-Ferrer S., Magnon C., Kunisaki Y., et al. Norepinephrine reuptake inhibition promotes mobilization in mice: potential impact to rescue low stem cell yields. Blood 2012, 119:3962-3965.
74. Spiegel A., Shivtiel S., Kalinkovich A., Ludin A., Netzer N., Goichberg P., et al. Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling. Nat Immunol 2007, 8:1123-1131.
75. Kawamori Y., Katayama Y., Asada N., Minagawa K., Sato M., Okamura A., et al. Role for vitamin D receptor in the neuronal control of the hematopoietic stem cell niche. Blood 2010, 116:5528-5535.
76. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
77. Albiero M., Poncina N., Tjwa M., Ciciliot S., Menegazzo L., Ceolotto G., et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes 2014, 63:1353-1365.
78. Fadini G.P., Albiero M., Vigili de Kreutzenberg S., Boscaro E., Cappellari R., Marescotti M., et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013, 36:943-949.
79. Bonig H., Papayannopoulou T. Hematopoietic stem cell mobilization: updated conceptual renditions. Leukemia 2013, 27:24-31.
80. Benboubker L., Watier H., Carion A., Georget M.T., Desbois I., Colombat P., et al. Association between the SDF1-3'A allele and high levels of CD34(+) progenitor cells mobilized into peripheral blood in humans. Br J Haematol 2001, 113:247-250.
81. Ben Nasr M., Reguaya Z., Berraies L., Maamar M., Ladeb S., Ben Othmen T., et al. Association of stromal cell-derived factor-1-3'A polymorphism to higher mobilization of hematopoietic stem cells CD34+ in Tunisian population. Transplant Proc 2011, 43:635-638.
82. Bogunia-Kubik K., Gieryng A., Dlubek D., Lange A. The CXCL12-3'A allele is associated with a higher mobilization yield of CD34 progenitors to the peripheral blood of healthy donors for allogeneic transplantation. Bone Marrow Transplant 2009, 44:273-278.
83. Martin-Antonio B., Carmona M., Falantes J., Gil E., Baez A., Suarez M., et al. Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors. Haematologica 2011, 96:102-109.
84. Lenk J., Bornhauser M., Kramer M., Holig K., Poppe-Thiede K., Schmidt H., et al. Sex and body mass index but not CXCL12 801 G/A polymorphism determine the efficacy of hematopoietic cell mobilization: a study in healthy volunteer donors. Biol Blood Marrow Transplant 2013, 19:1517-1521.
85. Szmigielska-Kaplon A., Szemraj J., Hamara K., Robak M., Wolska A., Pluta A., et al. Polymorphism of CD44 influences the efficacy of CD 34+ cells mobilization in patients with hematological malignancies. Biol Blood Marrow Transplant 2014, 20(7):986-991.
86. Clark R.E., Brammer C.G. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998, 22:859-863.
87. Tournilhac O., Cazin B., Lepretre S., Divine M., Maloum K., Delmer A., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004, 103:363-365.
88. Kumar S., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., Gastineau D.A., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
89. Banfi A., Podesta M., Fazzuoli L., Sertoli M.R., Venturini M., Santini G., et al. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 2001, 92:2419-2428.
90. Kemp K., Morse R., Wexler S., Cox C., Mallam E., Hows J., et al. Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy. Ann Hematol 2010, 89:701-713.
91. Noach E.J., Ausema A., van Os R., Akkerman I., Koopal S., Weersing E., et al. Chemotherapy prior to autologous bone marrow transplantation impairs long-term engraftment in mice. Exp Hematol 2003, 31:528-534.
92. Galotto M., Berisso G., Delfino L., Podesta M., Ottaggio L., Dallorso S., et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999, 27:1460-1466.
93. Lucas D., Scheiermann C., Chow A., Kunisaki Y., Bruns I., Barrick C., et al. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med 2013, 19:695-703.
94. Busik J.V., Tikhonenko M., Bhatwadekar A., Opreanu M., Yakubova N., Caballero S., et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med 2009, 206:2897-2906.
95. Said G. Focal and multifocal diabetic neuropathies. Arq Neuropsiquiatr 2007, 65:1272-1278.
96. Pulsipher M.A., Chitphakdithai P., Logan B.R., Shaw B.E., Wingard J.R., Lazarus H.M., et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood 2013, 121:197-206.
97. Halter J., Kodera Y., Ispizua A.U., Greinix H.T., Schmitz N., Favre G., et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009, 94:94-101.
98. Holig K., Kramer M., Kroschinsky F., Bornhauser M., Mengling T., Schmidt A.H., et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009, 114:3757-3763.
99. Rhodes B., Anderlini P. Allogeneic peripheral blood stem cell collection as of 2008. Transfus Apher Sci 2008, 38:219-227.
100. Azoulay E., Attalah H., Harf A., Schlemmer B., Delclaux C. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 2001, 120:1695-1701.
101. D'Souza A., Jaiyesimi I., Trainor L., Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 2008, 22:280-290.
102. Gianni A.M., Siena S., Bregni M., Tarella C., Stern A.C., Pileri A., et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989, 2:580-585.
103. Brasel K., McKenna H.J., Charrier K., Morrissey P.J., Williams D.E., Lyman S.D. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 1997, 90:3781-3788.
104. Laterveer L., Lindley I.J., Hamilton M.S., Willemze R., Fibbe W.E. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood 1995, 85:2269-2275.
105. Molineux G., Migdalska A., Szmitkowski M., Zsebo K., Dexter T.M. The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulating factor. Blood 1991, 78:961-966.
106. Lucas D., Battista M., Shi P.A., Isola L., Frenette P.S. Mobilized hematopoietic stem cell yield depends on species-specific circadian timing. Cell Stem Cell 2008, 3:364-366.
107. Broxmeyer H., Orschell C., Clapp D., Hangoc G., Cooper S., Plett P., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
108. Molineux G., Pojda Z., Dexter T.M. A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood 1990, 75:563-569.
109. Ramirez P., Rettig M.P., Uy G.L., Deych E., Holt M.S., Ritchey J.K., et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009, 114:1340-1343.
110. Tashiro K., Tada H., Heilker R., Shirozu M., Nakano T., Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993, 261:600-603.
111. Kawaguchi A., Orba Y., Kimura T., Iha H., Ogata M., Tsuji T., et al. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood 2009, 114:2961-2968.
112. Debnath B., Xu S., Grande F., Garofalo A., Neamati N. Small molecule inhibitors of CXCR4. Theranostics 2013, 3:47-75.
113. Ludin C., DeMarco S., Chiesa J., Kornelissen K., Brooks A., Heyes L. Evaluation of safety and efficacy of POL6326 for mobilisation of haematopoietic progenitor cells. 34th annual meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24th meeting of the EBMT-Nurses-Group/7th meeting of the EBMT-Data-Management-Group 2008, S128-S. Bone Marrow Transplantation, Nature Publishing Group, Florence, Italy.
114. First results of a Phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HSC) in multiple myeloma (MM). 52nd annual meeting of the American-Society-of-Hematology (ASH) 2010, Blood, Orlando, FL. S. Schmitt, N. Weinhold, K. Dembowsky, K. Neben, M. Witzens-Harig, M. Braun (Eds.).
115. Rapid mobilization of murine hematopoietic stem and progenitor cells with TG-0054, a novel CXCR4 antagonist. 51st annual meeting of the American-Society-of-Hematology 2009, Blood, New Orleans, LA. Y. Huang, Y. Liu, C. Yen, H. Chen, S. Chen, C. King (Eds.).
116. TG-0054, a novel and potent stem cell mobilizer, displays excellent PK/PD and safety profile in Phase I trial. 51st annual meeting of the American-Society-of-Hematology 2009, Blood, New Orleans, LA. D. Chung, L. Chang, Y. Huang, C. Tsai, C. Hsu, C. King (Eds.).
117. Rapid mobilization of CD34+ progenitor cells with TG0054-03, a novel CXC chemokine receptor 4 (CXCR4) antagonist. 55th ASH annual meeting and exposition 2013, Blood, New Orleans, LA. M. Schuster, N. Hagog, B. Jalilizeinali, S. Funkhauser, M. Yohannan, J. Sadler (Eds.).
118. ALT-1188: a new CXCR4 antagonist in development for mobilization of HSPCs. 55th ASH annual meeting and exhibition 2013, Blood, New Orleans, FL. M. Rettig, A. Ghobadi, M. Holt, S. Meier, J. Ritchey, Y. Tahirovic (Eds.).
119. Craddock C.F., Nakamoto B., Andrews R.G., Priestley G.V., Papayannopoulou T. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997, 90:4779-4788.
120. Kook S., Cho J., Lee S.B., Lee B.C. The nucleotide sugar UDP-glucose mobilizes long-term repopulating primitive hematopoietic cells. J Clin Invest 2013, 123:3420-3435.
121. Abbracchio M.P., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C., Miras-Portugal M.T., et al. Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 2003, 24:52-55.
122. Brautigam V.M., Dubyak G.R., Crain J.M., Watters J.J. The inflammatory effects of UDP-glucose in N9 microglia are not mediated by P2Y14 receptor activation. Purinergic Signal 2008, 4:73-78.
123. Scrivens M., Dickenson J.M. Pharmacological effects mediated by UDP-glucose that are independent of P2Y14 receptor expression. Pharmacol Res 2005, 51:533-538.
124. Jo E., Sanna M.G., Gonzalez-Cabrera P.J., Thangada S., Tigyi G., Osborne D.A., et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005, 12:703-715.
125. Budde K., Schmouder R.L., Brunkhorst R., Nashan B., Lucker P.W., Mayer T., et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002, 13:1073-1083.
126. Zhang J., Ren X., Shi W., Wang S., Chen H., Zhang B., et al. Small molecule Me6TREN mobilizes hematopoietic stem/progenitor cells by activating MMP-9 expression and disrupting SDF-1/CXCR4 axis. Blood 2014, 123:428-441.
127. Manabe A., Coustan-Smith E., Behm F., Raimondi S., Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992, 79:2370-2377.
128. Bendall L.J., Daniel A., Kortlepel K., Gottlieb D.J. Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol 1994, 22:1252-1260.
129. Panayiotidis P., Jones D., Ganeshaguru K., Foroni L., Hoffbrand A.V. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996, 92:97-103.
130. Mudry R.E., Fortney J.E., York T., Hall B.M., Gibson L.F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000, 96:1926-1932.
131. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158-1165.
132. Miyauchi J., Kelleher C.A., Wang C., Minkin S., McCulloch E.A. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989, 73:1272-1278.
133. Estey E.H., Thall P.F., Pierce S., Cortes J., Beran M., Kantarjian H., et al. Randomized phase II study of fludarabine+cytosine arabinoside+idarubicin±all-trans retinoic acid±granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999, 93:2478-2484.
134. Ohno R., Naoe T., Kanamaru A., Yoshida M., Hiraoka A., Kobayashi T., et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994, 83:2086-2092.
135. Buchner T., Berdel W.E., Hiddemann W. Priming with granulocyte colony-stimulating factor-relation to high-dose cytarabine in acute myeloid leukemia. N Engl J Med 2004, 350:2215-2216.
136. Amadori S., Suciu S., Jehn U., Stasi R., Thomas X., Marie J.P., et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005, 106:27-34.
137. Lowenberg B., van Putten W., Theobald M., Gmur J., Verdonck L., Sonneveld P., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349:743-752.
138. Pabst T., Vellenga E., van Putten W., Schouten H.C., Graux C., Vekemans M.C., et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012, 119:5367-5373.
139. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., Ritchey J.K., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
140. Uy G.L., Rettig M.P., Motabi I.H., McFarland K., Trinkaus K.M., Hladnik L.M., et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012, 119:3917-3924.
141. Weisberg E., Azab A.K., Manley P.W., Kung A.L., Christie A.L., Bronson R., et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012, 26:985-990.
142. Agarwal A., Fleischman A.G., Petersen C.L., MacKenzie R., Luty S., Loriaux M., et al. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood 2012, 120:2658-2668.
143. Handa A., Kashimura T., Takeuchi S., Yamamoto A., Murohashi I., Bessho M., et al. Expression of functional granulocyte colony-stimulating factor receptors on human B-lymphocytic leukemia cells. Ann Hematol 2000, 79:127-131.
144. Parameswaran R., Yu M., Lim M., Groffen J., Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 2011, 25(8):1314-1323.
145. Welschinger R., Liedtke F., Basnett J., Dela Pena A., Juarez J.G., Bradstock K.F., et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol 2012, 41:293-302.
146. Uy G., Stock W., Hsu Y.-M., Churpek J.E., Westervelt P., DiPersio J., et al. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. 55th ASH annual meeting and exposition 2013, 1398. American Society of Hematology, New Orleans. B. Löwenberg (Ed.).
147. Basnett J., Cisterne A., Bradstock K., Bendall L. Effects of G-CSF on acute lymphoblastic leukemia. 54th ASH annual meeting and exposition 2012, 2564. American Society of Hematology, Atlanta, GA. R.V. Ettan (Ed.).